Načítá se...
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
BACKGROUND: Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high‐affinity, humanized, IgG1κ, anti‐interleukin‐23 monoclonal antibody, for treating moderate‐to‐severe plaque psoriasis in the first 28 weeks. OBJECTIVES: To examine the effica...
Uloženo v:
| Vydáno v: | J Eur Acad Dermatol Venereol |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899626/ https://ncbi.nlm.nih.gov/pubmed/31407394 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.15862 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|